CA2498267A1 - Method for treating erectile dysfunction and increasing libido in men - Google Patents
Method for treating erectile dysfunction and increasing libido in menInfo
- Publication number
- CA2498267A1 CA2498267A1 CA002498267A CA2498267A CA2498267A1 CA 2498267 A1 CA2498267 A1 CA 2498267A1 CA 002498267 A CA002498267 A CA 002498267A CA 2498267 A CA2498267 A CA 2498267A CA 2498267 A1 CA2498267 A1 CA 2498267A1
- Authority
- CA
- Canada
- Prior art keywords
- testosterone
- steroid
- men
- enhancer
- isopropyl myristate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 52
- 201000001881 impotence Diseases 0.000 title claims abstract 6
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract 52
- 229960003604 testosterone Drugs 0.000 claims abstract 26
- 239000000203 mixture Substances 0.000 claims abstract 12
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims abstract 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 230000035936 sexual power Effects 0.000 claims abstract 3
- 229940094720 viagra Drugs 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 27
- 150000003431 steroids Chemical class 0.000 claims 14
- 239000003623 enhancer Substances 0.000 claims 11
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 9
- 239000002562 thickening agent Substances 0.000 claims 9
- 229920002125 Sokalan® Polymers 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 239000003961 penetration enhancing agent Substances 0.000 claims 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 6
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 4
- 206010052649 Primary hypogonadism Diseases 0.000 claims 3
- 210000001015 abdomen Anatomy 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 230000003054 hormonal effect Effects 0.000 claims 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims 2
- 229960000711 alprostadil Drugs 0.000 claims 2
- 229960004046 apomorphine Drugs 0.000 claims 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 2
- CXWQXGNFZLHLHQ-DPFCLETOSA-N apomorphine hydrochloride Chemical compound [H+].[H+].O.[Cl-].[Cl-].C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 CXWQXGNFZLHLHQ-DPFCLETOSA-N 0.000 claims 2
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims 2
- -1 papavaerine Chemical compound 0.000 claims 2
- 229960001476 pentoxifylline Drugs 0.000 claims 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001999 phentolamine Drugs 0.000 claims 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960002639 sildenafil citrate Drugs 0.000 claims 2
- 229960000317 yohimbine Drugs 0.000 claims 2
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims 2
- IVOJLNSQLGMYAO-AWEZNQCLSA-N (3s)-3-[[6-[[(3-methylsulfonylphenyl)sulfonylamino]methyl]pyridine-3-carbonyl]amino]-4-oxobutanoic acid Chemical compound CS(=O)(=O)C1=CC=CC(S(=O)(=O)NCC=2N=CC(=CC=2)C(=O)N[C@@H](CC(O)=O)C=O)=C1 IVOJLNSQLGMYAO-AWEZNQCLSA-N 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000036556 skin irritation Effects 0.000 abstract 1
- 231100000475 skin irritation Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic hormone profile with little or no skin irritation. The gel may be used as a method of improving sexual performance, including treating erectile dysfunction, and increasing libido by increasing testosterone levels in men. In addition, the gel may be used in conjunction with pharmaceuticals aimed at treating erectile dysfunction, such as VIAGRA®, to enhance their effectiveness.
Claims (54)
1. A method of improving the sexual performance in a male subject, comprising:
percutaneously delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject via a pharmaceutical composition comprising the steroid, at least one of a C1-C4 alcohol, and a penetration enhancer.
percutaneously delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject via a pharmaceutical composition comprising the steroid, at least one of a C1-C4 alcohol, and a penetration enhancer.
2, The method in claim 1 wherein the penetration enhancer comprises at least one of a C8-C22 fatty acid.
3. The method in claim 1 wherein the fatty acid comprises an alkyl chain length of at least 12 carbon atoms.
4. The method in claim 1 wherein the lower alcohol comprises at least one of ethanol, 2-propanol, n-propanol, and mixtures thereof.
5. The method in claim 1 wherein the the steroid is testosterone and the enhancer is isopropyl myristate.
6. The method of claim 5 wherein the composition comprises about 1.0 g w/w of testosterone.
7. The method of claim 5 wherein the enhancer comprises about 0.5 g w/w of isopropyl myristate.
8. The method of claim 5 wherein the thickener is CARBOPOL.
9. The method of claim 1 where the steroid comprises about 0.5 g to about 5.0 g testosterone, the thickener comprises about 0.10 g to about 2 g of CARBOPOL, the enhancer comprises about 0.1 g to about 2 g of isopropyl myristate, the C1 -C4 alcohol comprises about 40.0 g to about 90 g of ethanol.
10. The method in claim 1 wherein the men are hypogonadal.
57 17. The method in claim 10 wherein the men suffer from primary hypogonadism.,
12. The method in claim 1 wherein the delivering occurs daily.
13. The method in claim 12 wherein the delivery comprises administering the composition to the right/left upper arms/shoulders and to the right/left sides of the abdomen once per day on alternate days.
14. The method in claim 1 wherein the pharmaceutically effective amount of steroid comprises 75 mg of testosterone per day.
15. The method in claim 14 wherein the men achieve hormonal steady state levels of testosterone.
16. The method in claim 1 wherein the improving sexual performance comprises treating impotence in the men.
17. A method of increasing the libido of men comprising:
delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the men percutaneously in a composition comprised of a C1-alcohol, a penetration enhancer, a thickener, testosterone, and water.
delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the men percutaneously in a composition comprised of a C1-alcohol, a penetration enhancer, a thickener, testosterone, and water.
18. The method in claim 17 wherein the penetration enhancer comprises at least one of a C8-C22 fatty acid.
19. The method in claim 17 wherein the fatty acid comprises an alkyl chain length of at least 12 carbon atoms.
20. The method in claim 17 wherein the lower alcohol comprises at least one of ethanol, 2-propanol, n-propanol, and mixture thereof.
21. The method in claim 17 wherein the steroid is testosterone and the enhancer is isopropyl myristate.
22. The method of claim 21 wherein the composition comprises about 1.0 g w/w of testosterone.
23. The method of claim 21 wherein the enhancer comprises about 0.5 g w/w of isopropyl myristate.
24. The method of claim 21 wherein the thickener is CARBOPOL.
25. The method of claim 17 where the steroid comprises about 0.5 g to about 5.0 g testosterone, the thickener comprises about 0.10 g to about 2 g of CARBOPOL, the enhancer comprises about 0.1 g to about 2 g of isopropyl myristate, the C1-C4 alcohol comprises about 40.0 g to about 90 g of ethanol.
26. The method in claim 17 wherein the men are hypogonadal.
27. The method in claim 17 wherein the men suffer from primary hypogonadism.
28. The method in claim 17 wherein the delivering occurs daily.
29. The method in claim 28 wherein the delivery comprises administering the composition to the right/left upper arms/shoulders and to the right/left sides of the abdomen once per day on alternate days.
30. The method in claim 17 wherein the pharmaceutically effective amount of a steroid in the testosterone synthetic pathway comprises 75 mg of testosterone per day.
31. The method in claim 17 wherein the men achieve hormonal steady state levels of testosterone.
32. A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:
percutaneously delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject in a composition comprising at least one of a C1-C4 alcohol, the steroid, and a penetration enhancer; and administering the pharmaceutical to the subject.
percutaneously delivering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject in a composition comprising at least one of a C1-C4 alcohol, the steroid, and a penetration enhancer; and administering the pharmaceutical to the subject.
33. The method in claim 32 wherein the subject is eugonadal.
34. The method of claim 32 wherein the pharmaceutical is a phosphodiesterase type 5 inhibitor.
35. The method in claim 32 wherein the pharmaceutical is at least one of sildenafil citrate, pentoxifylline, yohimbine, apomorphine, alprostadil, papavaerine, phentolamine, and combinations, salts, derivatives and enantiomers of thereof
34. The method of claim 32 wherein the pharmaceutical is a phosphodiesterase type 5 inhibitor.
35. The method in claim 32 wherein the pharmaceutical is at least one of sildenafil citrate, pentoxifylline, yohimbine, apomorphine, alprostadil, papavaerine, phentolamine, and combinations, salts, derivatives and enantiomers of thereof
34. The method in claim 32 wherein the pharmaceuticals are selected from the group consisting of VIAGRA, UPRIMA, TRENTAL or ACTIBINE.
35. ~The method in claim 32 wherein the penetration enhancer comprises at least one of a C8-C22 fatty acid.
36. The method in claim 32 wherein the fatty acid comprises an alkyl chain length of at least 12 carbon atoms.
37. The method in claim 32 wherein the lower alcohol comprises at least one of ethanol, 2-propanol, n-propanol, and mixtures thereof.
38. The method in claim 32 wherein the the steroid is testosterone and the enhancer is isopropyl myristate.
39. The method of claim 38 wherein the composition comprises about 1.0 g w/w of testosterone.
40. ~The method of claim 38 wherein the enhancer comprises about 0.5 g w/w of isopropyl myristate.
41. The method of claim 38 wherein the thickener is CARBOPOL.
42. The method of claim 32 where the steroid comprises about 0.5 g to about 5.0 g testosterone, the thickener comprises about 0.10 g to about 2 g of CARBOPOL, the enhancer comprises about 0.1 g to about 2 g of isopropyl myristate, the C1-C4 alcohol comprises about 40.0 g to about 90 g of ethanol.
43. The method in claim 32 wherein the men are hypogonadal.
44. The method in claim 32 wherein the men suffer from primary hypogonadism.
45. The method in claim 32 wherein the delivering occurs daily.
46. The method in claim 32 wherein the delivery comprises administering the composition to the right/left upper arms/shoulders and to the right/left sides of the abdomen once per day on alternate days.
47. The method in claim 32 wherein the pharmaceutically effective amount steroid comprises 75 mg of testosterone per day.
48. The method in claim 32 wherein the men achieve hormonal steady state levels of testosterone.
49. A kit comprised of a pharmaceutical useful for treating erectile dysfunction in a man and a transdermal testosterone gel.
50. The kit of claim 49 wherein the pharmaceutical is a phosphodiesterase type inhibitor
51. The kit in claim 49 wherein the pharmaceutical is at least one of sildenafil citrate, pentoxifylline, yohimbine, apomorphine, alprostadil, papavaerine, phentolamine, and combinations, salts, derivatives and enantiomers of thereof
52. The kit in claim 49 wherein the pharmaceuticals are selected from the group consisting of VIAGRA, UPRIMA, TRENTAL or ACTIBINE.
53. The kit of claim 49 wherein the testosterone gel comprises about 0.5 g to about 5.0 g testosterone, a thickener, an enhancer, and a C1-C4 alcohol.
54. The kit of claim 53 wherein the thickener comprises about 0.10 g to about 2 g of CARBOPOL, the enhancer comprises about 0.1 g to about 2 g of isopropyl myristate, the C1-C4 alcohol comprises about 40.0 g to about 90 g of ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2498267A CA2498267C (en) | 2001-08-29 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2498267A CA2498267C (en) | 2001-08-29 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
| CA002420895A CA2420895C (en) | 2000-08-30 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002420895A Division CA2420895C (en) | 2000-08-30 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2498267A1 true CA2498267A1 (en) | 2002-03-07 |
| CA2498267C CA2498267C (en) | 2010-10-26 |
Family
ID=34427647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2498267A Expired - Lifetime CA2498267C (en) | 2001-08-29 | 2001-08-29 | Method for treating erectile dysfunction and increasing libido in men |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2498267C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061689A1 (en) * | 2004-12-10 | 2006-06-15 | Alan Drizen | Topical drug delivery system |
-
2001
- 2001-08-29 CA CA2498267A patent/CA2498267C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006061689A1 (en) * | 2004-12-10 | 2006-06-15 | Alan Drizen | Topical drug delivery system |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2498267C (en) | 2010-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2330188T3 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A GEL OR A SOLUTION BASED ON DIHYDROTESTOTERONE, ITS PREPARATION PROCEDURE AND ITS USES. | |
| CA2646667C (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| US20030139384A1 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| EP1510213B1 (en) | Penetration enhancing and irritation reducing systems comprising testosterone | |
| AU2001286995B2 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| DK2398457T3 (en) | TOPICAL FORMULATION clobetasol propionate LOW DOSE FOR TREATMENT OF DISEASES skin and mucous membranes | |
| JP2004524267A5 (en) | ||
| EP2173323B1 (en) | Stimulating gel | |
| US5747070A (en) | Methods for the treatment of herpes virus infections | |
| US20130079304A1 (en) | Pharmaceutical Compositions for the Treatment of Fungal Infections | |
| US6500440B1 (en) | Topical preparation of alprostadil for the treatment of erectile dysfunction | |
| US10993934B2 (en) | Topical compositions of dutasteride | |
| CA2498267A1 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| WO2004030665A1 (en) | Transparent gel composition, for the administration of diclofenac sodium through the skin | |
| RU2003108500A (en) | METHOD FOR TREATING ERECTILE DYSFUNCTION AND IMPROVEMENT OF LIBIDO IN MEN | |
| US20120238535A1 (en) | Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes | |
| WO2002102385A1 (en) | Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis | |
| CN1491647A (en) | Composition for percutaneous treating impotence and female sexual cold and preventing sextual disease | |
| US20090018214A1 (en) | Composition for Promoting Vascular Smooth Muscle Relaxation | |
| CN110996909A (en) | Surface composition | |
| US20180147138A1 (en) | Transdermal liquid preparation | |
| US11141387B2 (en) | Memantine-containing transdermally absorbable liquid | |
| WO2016028903A1 (en) | Oral transmucosal pharmaceutical compositions including testosterone and a c-sperm | |
| CN111419902A (en) | Composite lubricant for improving female climax probability and condom | |
| CA2559748A1 (en) | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210830 |